Liquid Biopsy Market, By Biomarker Type (CTC (Circulating Tumor Cells), ctNA (Circulating Tumor Nucliec Acids), Exosomes), By Sample Type (Blood, Urine, Others), By Disease Indication (Lung Cancer, Gastrointestinal Cancer, Prostate Cancer, Breast Cancer,

Liquid Biopsy Market, By Biomarker Type (CTC (Circulating Tumor Cells), ctNA (Circulating Tumor Nucliec Acids), Exosomes), By Sample Type (Blood, Urine, Others), By Disease Indication (Lung Cancer, Gastrointestinal Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Others), By End User (Hospitals, Cancer Institutes, Academic Institutes, Diagnostic Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Liquid biopsy is an advanced non-invasive cancer diagnostic technique that uses bio-fluids such as blood, cerebrospinal fluid (CSF), plasma, and urine for detecting cancer. Liquid biopsy uses circulating nucleic acids, circulating tumor cells (CTC), and exosomes as biomarkers for diagnosis of cancer. Increasing demand for non-invasive diagnostic procedures is expected to boost growth of the global liquid biopsy market over the forecast period. Furthermore, increasing prevalence of cancer is a major factor propelling growth of the global liquid biopsy market over the forecast period.
Key features of the study:
This report provides in-depth analysis of the global Liquid Biopsy and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global Liquid Biopsy based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Biocept, Inc., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global Liquid Biopsy report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Liquid Biopsy Market, By Biomarker Type:
CTC (Circulating Tumor Cells)
ctNA (Circulating Tumor Nucliec Acids)
Exosomes
Liquid Biopsy Market, By Sample Type:
Blood
Urine
Others
Liquid Biopsy Market, By Disease Indication:
Lung Cancer
Gastrointestinal Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others
Liquid Biopsy Market, By End User:
Hospitals
Cancer Institutes
Academic Institutes
Diagnostic Centers
Liquid Biopsy Market, By Region:
North America
By Biomarker Type:
CTC (Circulating Tumor Cells)
ctNA (Circulating Tumor Nucliec Acids)
Exosomes
By Sample Type
Blood
Urine
Others
By Disease Indication
Lung Cancer
Gastrointestinal Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others
By End User
Hospitals
Cancer Institutes
Academic Institutes
Diagnostic Centers
By Country:
U.S.
Canada
Latin America
By Biomarker Type:
CTC (Circulating Tumor Cells)
ctNA (Circulating Tumor Nucliec Acids)
Exosomes
By Sample Type
Blood
Urine
Others
By Disease Indication
Lung Cancer
Gastrointestinal Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others
By End User
Hospitals
Cancer Institutes
Academic Institutes
Diagnostic Centers
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Biomarker Type:
CTC (Circulating Tumor Cells)
ctNA (Circulating Tumor Nucliec Acids)
Exosomes
By Sample Type
Blood
Urine
Others
By Disease Indication
Lung Cancer
Gastrointestinal Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others
By End User
Hospitals
Cancer Institutes
Academic Institutes
Diagnostic Centers
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Biomarker Type:
CTC (Circulating Tumor Cells)
ctNA (Circulating Tumor Nucliec Acids)
Exosomes
By Sample Type
Blood
Urine
Others
By Disease Indication
Lung Cancer
Gastrointestinal Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others
By End User
Hospitals
Cancer Institutes
Academic Institutes
Diagnostic Centers
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Biomarker Type:
CTC (Circulating Tumor Cells)
ctNA (Circulating Tumor Nucliec Acids)
Exosomes
By Sample Type
Blood
Urine
Others
By Disease Indication
Lung Cancer
Gastrointestinal Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others
By End User
Hospitals
Cancer Institutes
Academic Institutes
Diagnostic Centers
By Country:
GCC
Israel
Rest of Middle East
Africa
By Biomarker Type:
CTC (Circulating Tumor Cells)
ctNA (Circulating Tumor Nucliec Acids)
Exosomes
By Sample Type
Blood
Urine
Others
By Disease Indication
Lung Cancer
Gastrointestinal Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others
By End User
Hospitals
Cancer Institutes
Academic Institutes
Diagnostic Centers
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Biocept, Inc. *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Qiagen N.V
Trovagene, Inc.
Janssen Global Services, LLC
MDxHealth SA
Natera, Inc.
F. Hoffmann-La Roche Ltd.
Silicon Biosystems
Pathway Genomics Corporation
Sysmex Corporation
“*” marked represents similar segmentation in other categories in the respective section.